Key Performance
More- Earnings Score: 17
- Momentum Score: 28
- True Yield: N/A
- Financial Health Score: 37
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Capricor (CAPR) Q2 2026 Earnings Call Transcript
Capricor Therapeutics reported Q2 2026 results with a net loss of $40.7 million ($0.70 per share) and cash reserves of $237.9 million. The company faced a significant setback when the FDA Advisory Committee voted 3-9 against approving Deramiocel for cardiomyopathy in DMD patients. However, management plans to submit a BLA amendment focusing on upper limb skeletal muscle function, supported by positive HOPE-3 primary endpoint data showing statistically significant slowing of disease progression (p=0.029). The company is scaling manufacturing capacity and pursuing arbitration with NS Pharma over distribution agreement disputes.
08/20/2026, 6:08 PM • The Motley Fool
A class action lawsuit has been filed against Capricor Therapeutics for allegedly making false statements regarding changes to its statistical analysis plan for the Deramiocel drug candidate without FDA approval. The FDA's briefing documents revealed concerns about the integrity of the clinical data analysis, leading to a 64% stock price decline on July 27, 2026, followed by a 36% decline after an advisory committee voted against the drug's efficacy on July 29, 2026.
08/10/2026, 7:50 AM • GlobeNewswire
A class action lawsuit has been filed against Capricor Therapeutics (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025 and July 26, 2026. The lawsuit alleges that Capricor made materially false statements regarding changes to its statistical analysis plan for Deramiocel without FDA agreement, creating significant regulatory approval risks. Investors who purchased during this period may be entitled to compensation.
08/07/2026, 1:42 PM • GlobeNewswire
Rosen Law Firm has filed a class action lawsuit against Capricor Therapeutics (CAPR) on behalf of investors who purchased securities between December 17, 2025 and July 26, 2026. The lawsuit alleges that Capricor made materially false statements regarding changes to its statistical analysis plan for Deramiocel without FDA approval, creating significant regulatory risk for the cell therapy's approval for treating Duchenne muscular dystrophy. Investors must move the court by September 28, 2026 to serve as lead plaintiff.
08/04/2026, 7:44 PM • GlobeNewswire
Bernstein Liebhard LLP, an investor rights law firm, has announced investigations into potential breaches of fiduciary duty by directors and officers at AeroVironment, Capricor Therapeutics, and Calix. The firm is seeking to determine whether company leadership fulfilled obligations to shareholders and whether legal remedies may be available. Current shareholders are encouraged to contact the firm for consultation.
08/04/2026, 12:47 PM • GlobeNewswire
Bernstein Liebhard LLP has filed securities class action lawsuits against Wise Group plc, Capricor Therapeutics, Inc., and is investigating Calix, Inc. for alleged materially false and misleading statements regarding business operations and financial stability. Investors who purchased securities during specified periods are encouraged to contact the firm to discuss their rights and potential recovery.
08/04/2026, 12:47 PM • GlobeNewswire
Bernstein Liebhard LLP has launched investigations into potential breaches of fiduciary duty by directors and officers at CarMax, Inc., Capricor Therapeutics, Inc., and Calix, Inc. The firm is seeking to determine whether company leadership acted in shareholders' best interests and is encouraging affected shareholders to contact them for legal consultation.
08/04/2026, 12:47 PM • GlobeNewswire
A securities class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025 and July 6, 2026. The lawsuit alleges the company made materially false and misleading statements regarding business operations, growth prospects, and financial stability, causing securities to trade at artificially inflated prices. Investors who suffered losses are encouraged to contact the law firm or submit claims by September 28, 2026 to potentially serve as lead plaintiff.
08/04/2026, 12:47 PM • GlobeNewswire
Bernstein Liebhard LLP announced an investigation into potential breaches of fiduciary duty by directors and officers of Gartner, Inc. The law firm is seeking to determine whether company leadership fulfilled its obligations to shareholders. The investigation targets shareholders who purchased shares before February 24, 2025.
08/04/2026, 12:47 PM • GlobeNewswire
Bernstein Liebhard LLP has filed securities class action lawsuits against Avis Budget Group for allegedly orchestrating a market manipulation scheme involving short squeezes, and is investigating potential breaches of fiduciary duty at Capricor Therapeutics and Calix. Investors who suffered losses during the specified periods are encouraged to participate in the class actions.
08/04/2026, 12:47 PM • GlobeNewswire
Bernstein Liebhard LLP announced an investigation into potential breaches of fiduciary duty by directors and officers of Calix, Inc. The law firm is seeking to determine whether company leadership fulfilled its obligations to shareholders. The investigation focuses on shareholders who purchased shares before January 28, 2026.
08/04/2026, 12:47 PM • GlobeNewswire
A class action lawsuit has been filed against Capricor Therapeutics for allegedly making false statements about its lead drug candidate Deramiocel. The FDA rejected the drug application after discovering undisclosed changes to the statistical analysis plan, causing Capricor's stock to plummet 64% on July 27, 2026, and an additional 36% on July 29, 2026, following an advisory committee vote against the drug's efficacy.
08/04/2026, 7:45 AM • GlobeNewswire
A class action lawsuit has been filed against Capricor Therapeutics, Inc. alleging that the company made materially false and misleading statements regarding its Deramiocel drug candidate. The complaint claims Capricor changed its statistical analysis plan without FDA agreement and failed to disclose the significant risk that the FDA would reject the Biologics License Application, putting regulatory approval for treating Duchenne muscular dystrophy in jeopardy.
08/03/2026, 2:55 PM • GlobeNewswire
The Rosen Law Firm announced an investigation into Capricor Therapeutics Inc. following FDA staff concerns about effectiveness data for the company's experimental cell therapy (deramiocel) for a heart condition related to Duchenne muscular dystrophy. The disclosure caused Capricor's stock to plunge 64-65% on July 27, 2026. The firm is preparing a class action lawsuit to recover investor losses.
08/02/2026, 12:10 PM • GlobeNewswire
CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLC
The FDA announced that Capricor Therapeutics' stem cell treatment for Duchenne muscular dystrophy did not meet the objectives of its Phase 3 trial, contradicting the company's claims from the previous year. Following this disclosure, Capricor's stock price declined significantly.
07/30/2026, 1:52 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 08/21/2026
Company Profile
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.